Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vasa-1
- Development stage
- Unknown
- Lead developer
- Vasa Therapeutics
- Modality
- Small Molecules
01
Overview
Vasa-1 (also known as VT1) is a clinical-stage therapeutic candidate being developed by Orphinic Scientific for the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF) and diastolic heart failure. The drug utilizes a proprietary scaffold to target matrix metalloproteinases (MMPs), a family of enzymes involved in the remodeling of the cardiac extracellular matrix. In HFpEF, maladaptive MMP activity contributes to myocardial fibrosis and structural changes that impair cardiac relaxation and filling. By inhibiting MMP activity, Vasa-1 aims to mitigate these fibrotic processes and improve diastolic function, addressing a significant unmet need in cardiovascular medicine.
- Other names
- VT1VT-1VT 1
02
Targets
MMP13 (Matrix metalloproteinase-13)MMP2 (Matrix metalloproteinase-2)MMP9 (Matrix metalloproteinase-9)MMP12 (Macrophage Metalloelastase)
Beyond the preview
Go deeper on Vasa-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vasa-1.